OS Therapies Incorporated (OSTX)
XASE:OSTX
Want to see OSTX full AI Analyst Report?
OSTX Stock Chart & Stats
$1.44
$0.51(10.41%)
At close: 4:00 PM EST
$1.44
$0.51(10.41%)
Day’s Range― - ―
52-Week Range$1.15 - $2.57
Previous CloseN/A
Volume28.07K
Average Volume (3M)615.79K
Market Cap
$71.47M
Enterprise Value-$201.31M
Total Cash (Recent Filing)$269.83M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding42,038,300
10 Day Avg. Volume769,698
30 Day Avg. Volume615,790
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-2.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit554.44
Enterprise Value/Ebitda7.09
Forecast
1Y Price Target
$10.00Price Target Upside594.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$12.81M
Bulls Say, Bears Say
Bulls Say
Biomarker EvidenceSubmission of a clinical and biomarker data package indicates a biomarker-driven response profile, which can enable targeted patient selection and strengthen the therapy's clinical differentiation.
Clinical OutcomesMid-stage and late-stage trial results showing superior event-free and overall survival versus historical controls suggest a meaningful clinical benefit that could support adoption and valuation upside.
Bears Say
Confirmatory Trial RequirementAccelerated approval efforts are expected to require a confirmatory study, which could delay full approval and increase resource and trial execution demands.
Liquidity RiskA net loss and very low cash balance, combined with recent financing that provides only limited runway, create material near-term funding risk that could force dilutive capital raises.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.15 and its highest was $2.57 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $71.47M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is May 15, 2026 which is in 14 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on Apr 06, 2026. The company reported -$0.365 earnings per share for the quarter, missing the consensus estimate of -$0.177 by -$0.188.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 42,038,300 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.365 in its last earnings report, missing expectations of -$0.177. Following the earnings report the stock price went down -6.618%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (594.44% Upside)
$10.00 (594.44% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.15%
12-Months-Change
Fundamentals
Return on Equity
-1923.86%
Trailing 12-Months
Asset Growth
23.48%
Trailing 12-Months
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(594.44% Upside)
Technical Analysis
Ownership Overview
15.39% Insiders
1.47% Mutual Funds
0.69% Other Institutional Investors
81.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---